Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Xianjun Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6697-7143; OpenAlex author ID A5100374639. Sources: ClinicalTrials.gov.

Their work

Papers
305 (first author 4, last author 117)
Trials
16 (principal investigator on 13)
Grants
0
Labs led
1
Collaborators
343
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 3 papers · 2012: 5 papers · 2013: 11 papers · 2014: 10 papers · 2015: 15 papers · 2016: 16 papers · 2017: 15 papers · 2018: 28 papers · 2019: 34 papers, 6 trials · 2020: 30 papers · 2021: 33 papers, 3 trials · 2022: 19 papers · 2023: 30 papers, 3 trials · 2024: 29 papers, 2 trials · 2025: 15 papers · 2026: 12 papers, 1 trial

Papers 50 of 305

  1. Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer. Co-author DOI 10.1002/advs.202521844↗
  2. A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. Co-author DOI 10.1007/s00259-025-07609-0↗
  3. Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. Co-author DOI 10.1007/s00535-026-02468-4↗
  4. Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Last author DOI 10.1016/j.ccell.2026.05.012↗
  5. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Last author DOI 10.1016/j.ccell.2026.08.012↗
  6. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids. Co-author DOI 10.1016/j.pan.2026.07.013↗
  7. Corrigendum to "Wang X, Wang R, Lin X et al. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pa… Co-author DOI 10.1016/j.pan.2026.09.001↗
  8. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  9. GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence. Co-author DOI 10.1016/j.tranon.2026.103044↗
  10. Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer. Last author DOI 10.1038/s41467-026-73702-z↗
  11. Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibi… Co-author DOI 10.1136/gutjnl-2025-336235↗
  12. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2025.5822↗
  13. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  14. Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing. Co-author DOI 10.1007/s12672-025-02293-w↗
  15. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Co-author DOI 10.1016/j.tranon.2025.102346↗
  16. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Last author DOI 10.1016/j.xcrm.2025.102364↗
  17. A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adeno… Co-author DOI 10.1038/s41392-025-02530-2↗
  18. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  19. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Last author DOI 10.1053/j.gastro.2025.03.019↗
  20. SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. Co-author DOI 10.1097/cm9.0000000000003640↗
  21. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  22. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Last author DOI 10.1097/sla.0000000000006681↗
  23. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
  24. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Last author DOI 10.1136/gutjnl-2024-334361↗
  25. Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarci… Last author DOI 10.1186/s12916-025-04078-y↗
  26. Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030. Co-author DOI 10.3389/fonc.2025.1660313↗
  27. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. Co-author DOI 10.3724/abbs.2025111↗
  28. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Co-author DOI 10.1002/mc.23645↗
  29. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03648-y↗
  30. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03786-3↗
  31. Evaluating the efficacy of laparoscopic radical antegrade modular pancreatosplenectomy in selected early-stage left-sided pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-024-10868-x↗
  32. Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. Co-author DOI 10.1007/s13402-024-01022-9↗
  33. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167346↗
  34. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Last author DOI 10.1016/j.canlet.2024.216741↗
  35. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217197↗
  36. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  37. The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2024.09.032↗
  38. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ebiom.2024.105098↗
  39. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Co-author DOI 10.1016/j.redox.2024.103200↗
  40. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.019↗
  41. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41401-023-01199-z↗
  42. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02631-9↗
  43. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41419-024-06589-7↗
  44. Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics. Last author DOI 10.1097/sla.0000000000006168↗
  45. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Co-author DOI 10.1111/cpr.13694↗
  46. PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adk6633↗
  47. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  48. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Co-author DOI 10.1186/s12885-024-11842-5↗
  49. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma. Last author DOI 10.1186/s12916-024-03581-y↗
  50. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… Co-author DOI 10.1186/s12957-023-03277-2↗

Trials 16

  1. GST101 in Participants With RAS-Mutant Advanced Solid Tumors Study chair NCT07868172↗
  2. Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy Principal investigator NCT06167421↗
  3. Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT06492915↗
  4. Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors Principal investigator NCT05847855↗
  5. Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm Principal investigator NCT05907824↗
  6. LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer Principal investigator NCT05939063↗
  7. AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Principal investigator NCT04617821↗
  8. Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC Principal investigator NCT04855331↗
  9. The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Principal investigator NCT05168527↗
  10. Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer Study director NCT03929094↗
  11. Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen Study director NCT04101929↗
  12. Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer Principal investigator NCT04498689↗
  13. The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer Principal investigator NCT04581876↗
  14. Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction Principal investigator NCT06024343↗
  15. Pancreatic Fistula After Minimally Invasive Enucleation Principal investigator NCT06557408↗
  16. Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN Principal investigator NCT07592663↗

Closest collaborators

The 25 strongest of 343 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Si Shi · 114 shared papers, 2012–2026 · strength 14.75
  2. Jin Xu · 130 shared papers, 2011–2026 · strength 13.93
  3. Jie Hua · 64 shared papers, 2018–2026 · strength 9.22
  4. Qingcai Meng · 63 shared papers, 2017–2026 · strength 8.63
  5. Chen Liang · 67 shared papers, 2015–2026 · strength 7.76
  6. Chen Liu · 77 shared papers, 2011–2026 · strength 6.99
  7. Shunrong Ji · 55 shared papers, 1 shared trial, 2012–2025 · strength 6.04
  8. Quanxing Ni · 76 shared papers, 2012–2024 · strength 5.73
  9. Kaizhou Jin · 49 shared papers, 2015–2026 · strength 5.51
  10. Yi Qin · 57 shared papers, 2013–2025 · strength 4.92
  11. Wei Wang · 29 shared papers, 2021–2026 · strength 4.75
  12. Miaoyan Wei · 26 shared papers, 2019–2026 · strength 4.55
  13. Liang Liu · 60 shared papers, 2013–2026 · strength 4.51
  14. Bo Zhang · 30 shared papers, 2017–2024 · strength 4.30
  15. Guopei Luo · 50 shared papers, 2011–2025 · strength 4.24
  16. He Cheng · 33 shared papers, 2015–2026 · strength 4.04
  17. Huaxiang Xu · 39 shared papers, 2013–2026 · strength 3.64
  18. Xiaowu Xu · 25 shared papers, 2019–2025 · strength 3.46
  19. Wenyan Xu · 38 shared papers, 2012–2025 · strength 3.29
  20. Rong Tang · 18 shared papers, 2020–2026 · strength 3.10
  21. Weiding Wu · 15 shared papers, 2021–2026 · strength 2.85
  22. Zhen Tan · 17 shared papers, 2019–2026 · strength 2.84
  23. Xuan Lin · 17 shared papers, 2020–2025 · strength 2.77
  24. Xiaowu Xu · 7 shared papers, 4 shared trials, 2019–2025 · strength 2.72
  25. Long‐Yun Ye · 15 shared papers, 2020–2026 · strength 2.70

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.